|Bid||253.24 x 1000|
|Ask||256.30 x 1200|
|Day's Range||252.06 - 258.81|
|52 Week Range||210.28 - 276.69|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||20.92|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||7.04 (2.77%)|
|Ex-Dividend Date||May 14, 2021|
|1y Target Est||254.40|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 887 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results from the PATHFINDER clinical program including the pivotal NAVIGATOR Phase 3 trial, which demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma compared to placebo.1 Tezepelumab is the only biologic to consistently and significantly reduce AAER in a broad population of severe asthma patients irrespective of the baseline eosinophil counts across Phase 2 and Phase 3 clinical trials.
Readers hoping to buy Amgen Inc. ( NASDAQ:AMGN ) for its dividend will need to make their move shortly, as the stock is...